Literature DB >> 3092836

The effect of CS-514, an inhibitor of HMG-CoA reductase, on serum lipids in healthy volunteers.

N Nakaya, Y Homma, H Tamachi, Y Goto.   

Abstract

CS-514 is a competitive inhibitor of HMG-CoA reductase. The effect of this agent on serum lipids and lipoproteins was studied in 10 healthy normocholesterolemic male volunteers by giving 20 mg of CS-514 or placebo twice a day for 7 days under double-blind conditions. The mean total serum cholesterol level decreased by 18.6% in the CS-514 group, whereas it increased by 7.4% in the placebo group and the difference between the two groups was statistically significant (P less than 0.01). LDL cholesterol and LDL apo B values were reduced by 22.6% and 23.2%, respectively. Serum triglyceride level did not change significantly. No clinical or laboratory abnormalities were observed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3092836     DOI: 10.1016/0021-9150(86)90071-7

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

1.  Clinical pharmacology of the hypocholesterolemic agent K 12.148 (lifibrol) in healthy volunteers.

Authors:  H Hasibeder; H J Staab; K Seibel; B Heibel; G Schmidle; W März
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

3.  Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II.

Authors:  H Saxenhofer; P Weidmann; W F Riesen; C Beretta-Piccoli; C Fragiacomo; R Wunderlin; G Noseda
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 4.  Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.

Authors:  M Haria; D McTavish
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

5.  The effects of rosuvastatin on the serum cortisol, serum lipid, and serum mevalonic acid levels in the healthy Indian male population.

Authors:  Tanveer Ahmad Wani; Abdus Samad; Monika Tandon; Gurpreet S Saini; P L Sharma; K K Pillai
Journal:  AAPS PharmSciTech       Date:  2010-03-19       Impact factor: 3.246

Review 6.  Pravastatin: a review of its use in elderly patients.

Authors:  Lynne M Bang; Karen L Goa
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

7.  Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys.

Authors:  T Komai; K Kawai; T Tokui; Y Tokui; C Kuroiwa; E Shigehara; M Tanaka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Apr-Jun       Impact factor: 2.441

Review 8.  Clinical pharmacokinetics of pravastatin.

Authors:  J A Quion; P H Jones
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.